康芝药业： 苏拉明纳为公司的研发项目，目前因临床进展未达预期，已暂停后续推进

Group 1 - The core issue raised by investors is the lack of progress on the research and development project in Suriname, despite the government opening a green channel for the company [2] - The company, Kangzhi Pharmaceutical (300086.SZ), responded that the project has been paused due to clinical progress not meeting expectations and is currently undergoing internal evaluation and strategy adjustment [2] - The company emphasized the importance of investors being aware of investment risks and stated that it will fulfill its information disclosure obligations as required [2]